Kornimate/medical-research-clean huggingface dataset:
study on the design and application of special semi recumbent cushion for postoperative patients with esophageal cancer

Conditions: Esophageal Cancer

Summary: 1. transform and produce the authorized utility model invention patent "a special cushion for semi recumbent position". 2. to verify the effect of using special semi recumbent cushion for postoperative patients with esophageal cancer.

1. make application-oriented achievement transformation products to provide new special semi recumbent auxiliary tools for patients with esophageal cancer after operation. summarize the clinical experience and evidence, sign the project cooperation intention agreement with the manufacturer with production qualification, connect with the professional designer of the manufacturer and refine and improve the design scheme; the angle range, materials, fabrics and connection methods of the semi reclining cushion are closely combined with the clinical treatment and patient needs to meet the effectiveness, comfort and practicality of the patient's application; to produce semi reclining cushion products to provide semi reclining cushion for patients after esophageal cancer surgery that can be adjusted from multiple angles and take into account the skin protection function, which is conducive to preventing and alleviating reflux symptoms, improving the quality of life and reducing the risk of skin stress injury. 2. implement and evaluate the effectiveness of the special semi reclining cushion after esophageal cancer surgery, apply the product to patients after esophageal cancer surgery, and evaluate the effect.

Eligibility criteria:
inclusion criteria: 1. transform and produce the authorized utility model invention patent "a special cushion for semi recumbent position". 2. to verify the effect of using special semi recumbent cushion for postoperative patients with esophageal cancer. 1. patients with pathologically confirmed esophageal cancer who underwent thoracoscopic resection and neck anastomosis; 2. age ≥ 18 years old; 3. able to read and fill in the questionnaire independently. exclusion criteria: 1. cognitive impairment or mental illness; 2. complicated with other serious diseases; 3. unwilling to participate in this study.
non-hypovascular solid pancreatic lesions: role of eus

Conditions: Solid Pancreatic Neoplasms; Endoscopic Ultrasound

Summary: vascular pattern of solid pancreatic lesions (spls) has been investigated by different abdominal imaging modalities and by contrast-enhanced endoscopic ultrasonography (ce-eus). compared with surrounding pancreatic parenchyma three different patterns have been described: hypo-, iso-, and hypervascular. the majority of spls are hypovascular, and the diagnostic relevance of hypoenhanced pattern to predict pancreatic adenocarcinoma (pdac) is well established. differently, iso- and hypervascular pattern is not specific and can be expressed by several spls, with different clinical behavior and management. to date, poor is know about the role of eus in differential diagnosis of non-hypovascular spls and features associated with malignancy.


Eligibility criteria:
inclusion criteria: * presence of one or more solid pancreatic lesions preliminary evaluated by contrast-enhanced computed tomography (ce-ct) and/or contrast enhanced magnetic resonance imaging (ce-mri) reporting a non-hypovascular contrast pattern (e.g., iso- or hypervascular). exclusion criteria: * patients with associated chronic pancreatitis features (e.g., pancreatic calcifications) * lesion with hypovascular pattern at ce-eus. * lesion not found or non pancreatic at eus. * patients refusing to be included in the study
preventing taxane-related peripheral neuropathy, pain and nail toxicity: a prospective self-controlled trial comparing hilotherapy with frozen gloves in early breast cancer

Conditions: Breast Cancer

Summary: the prevention of taxane-related toxicities at the extremities is highly important for patients' treatment and quality-of-life. unlike standard cryotherapy with frozen gloves, hilotherapy produces cooling at a constant temperature. comparative data with frozen gloves are unavailable. this prospective self-controlled study explores the efficacy of hilotherapy at the right hand and foot compared to frozen gloves at the left in patients with early breast cancer treated with weekly paclitaxel 80 mg/m² or three-weekly docetaxel 75 mg/m².


Eligibility criteria:
inclusion criteria: * adult (≥18 years) patients with breast cancer * treated with weekly paclitaxel 80 mg/m² (12 cycles) or three-weekly docetaxel 75 mg/m² (4 or 6 cycles) in an adjuvant or neo-adjuvant setting. exclusion criteria: * peripheral neuropathy or pain in the extremities at baseline, regardless of whether this was related to a prior chemotherapy treatment or another condition * raynaud's phenomenon, cold intolerance or any condition to the nails or peripheral blood vessels that could pose a risk to the compliance with the study interventions * insufficient understanding of the dutch language for self-reporting the side-effects under investigation patients were excluded from the analysis if they received less than two thirds of planned treatment cycles, for other reasons than the side-effects investigated in this study.
combined inhibition of dipeptidyl peptidase iv (dpiv/cd26) and aminopeptidase n (apn/cd13) in the treatment of psoriasis

Conditions: Psoriasis

Summary: the major objective of this study is to evaluate the therapeutic effect of a topical treatment simultaneously inhibiting dipeptidyl peptidase iv and aminopeptidase n (imtm #ip10.c8) in patients with mild to moderate psoriasis of the skin


Eligibility criteria:
inclusion criteria: 1. age 18 years of age at pre-study and 2. diagnosis of plaque type psoriasis at least 3 month prior to enrolment 3. mild to moderate plaque type psoriasis with at least 2 plaques of approximately 15cm2 for which topical treatment is indicated 4. patients must be able to give written informed consent before any trial-specific procedures are performed (see section 12.2 exclusion criteria: 1. other type of psoriasis (e.g. erythrodermic, guttate or pustular) at enrolment 2. drug induced psoriasis at enrolment (e.g. lithium) 3. pregnant or lactating women, patients (men or women) planning a pregnancy during the duration of the study 4. systemic therapy affecting pasi or phototherapy for a period of 4 weeks prior to enrolment 5. topical therapy affecting pasi for a period of 2 weeks prior to enrolment 6. treatment with biologic agents affecting pasi for a period of 3 months prior to enrolment 7. systemic treatment with immunosuppressive agents (e.g. methotrexate, cyclosporin) or treatment with lithium, anti-malaria medication, or intramuscular gold application for a period of 4 weeks prior to enrolment 8. having a history of or an ongoing uncontrolled serious or recurring bacterial, viral, fungal, or atypical mycobacterial infection 9. having a severe medical condition that, in the judgment of the investigator, would jeopardize in any way the subject's safety following exposure to study drug 10. having the presence or history of malignancy, including lymphoproliferative disorders. subjects with a history of fully resolved basal or squamous cell skin cancer may be enrolled
symbolic representation in young children with down syndrome

Conditions: Down Syndrome

Summary: the aim of this study is to characterize the process of constitution of symbolic representation in infants with down syndrome, as well as to investigate the relationship between gestures and the emergence of oral language. the investigators hypothesis is that children with down syndrome could present difficulties during the constitution of symbolic representation that may be related to later deficits on expressive language, generally observed in these children.

according to the genetic epistemology, language development is directly related to cognitive construction. such relationship is clearly observed after the constitution of representation that allows one individual to express his or her thinking through language.

Eligibility criteria:
inclusion criteria for study group: * genetic diagnosis of down syndrome * be at the 4th stage of sensorimotor period at the initial assessment * good health conditions * good results on audiologic evaluation * pediatric and ear, nose and throat periodic check ups. inclusion criteria for control group: * good health conditions * be at the 4th stage of sensorimotor period at the initial assessment * pediatric and ear, nose and throat periodic check ups. exclusion criteria for all groups: * submission to long term hospitalizations due to heart diseases and major respiratory airway infections, that may interfere in the child's global development * presence of visual or auditory important deficits * historic of prematurely and/or low birth weight

Keywords: down syndrome symbolic representation gestures expressive language development
influenza vaccination in immunocompromized patients

Conditions: Immunosuppression

Summary: evaluation of the immunogenicity and reactogenicity of two different formulations of commercially avail-able influenza vaccines in 4 different groups of immunocompromized outpatients (hiv positive patients, patients suffering from rheumatologic diseases and receiving treatment with immunosuppressive drugs and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis). the aim of the study was to investigate if the newest formulation of influenza vaccines (virosomal vaccines) offer a benefit in immunocompromized patients in comparison to an older subunit formulation.

the infection with influenza is associated with higher morbidity and mortality in risk groups including immunocompromized patients. the virosomal influenza vaccines have been associated with improved immunogenicity in former trials. no direct comparison with older formulations has been conducted so far.

Eligibility criteria:
inclusion criteria: * adult outpatients treated at the inselspital bern for: * hiv infection * rheumatologic diseases and receiving immunosuppressive drugs * kidney transplant recipients * undergoing hemodialysis or continuous ambulatory peritoneal dialysis * written informed consent exclusion criteria: * allergy to egg proteins * former adverse reactions to prior vaccination * febrile conditions at the time of study inclusion

Keywords: influenza vaccination subunit virosomal hiv/aids renal dialysis kidney transplantation rheumatologic diseases immunogenicity reactogenicity
efficacy of exercise on quality of life and physical function in patients with knee osteoarthritis

Conditions: Osteoarthritis; Pain

Summary: the overall contribution of this study is to increase the knowledge of the efficacy of strength and aerobic exercise on knee related quality of life, knee pain, and physical function in patients with knee osteoarthritis (oa). knee oa is one of the most important diseases within musculoskeletal conditions affecting a considerable number of people worldwide. this randomized controlled trial will involve one intervention group delivered strength exercises and one group delivered aerobic exercise (ergometer cycling). the two intervention groups will be compared to a control group undergoing usual care. cost-effectiveness analysis will be performed comparing the three groups. the study is funded from the research council of norway.

the trial aimed to recruit 207 study participants randomly allocated to three arms. the participants had to have symptomatic knee osteoarthritis verified by grade 2-3 using the kellgren and lawrence radiographic classification system, and they had to have knee pain most of the days the last month and fulfil 2/3 of the acr clinical criteria. participants with other serious comorbidities or self-reported bmi \>35 were included. the interventions consisted of structured strength training program over 12-14 weeks, and a structured stationary cycling program for 12-14 weeks. primary outcome was the koos knee-related quality of life subscale at the 1 year follow-up. secondary outcomes were other patient reported outcomes, muscle strength, and peak oxygen consumption at the 4-month and 1 year follow-up, and over time (1-year).

Eligibility criteria:
inclusion criteria: * women and men aged 35-70 years * clinical knee oa according to the american college of rheumatology clinical criteria * kellgren and lawrence radiographic oa grade 2 and 3 (mild to moderate radiographic oa) exclusion criteria: * severe knee oa according to the kellgren and lawrence classification (grade 4) * other known major musculoskeletal impairments in the lower extremities or the back or prostheses in any joint of the lower extremities * known coronary heart diseases or cancer * body mass index \> 35 * scheduled for surgery in any joint * known mental or psychologic diseases * known drug abuse * persons who already perform sports related moderate physical activity more than two times a week * contraindications for magnetic resonance imaging (specific point list at oslo university hospital, radiographic department) * not speaking norwegian language

Keywords: osteoarthritis pain exercise function cartilage quality
hemodynamic effects of arni on noninvasive pressure-volume analysis in patients with chronic heart failure

Conditions: Heart Failure With Reduced Ejection Fraction

Summary: sacubitril-valsartan reduced heart failure hospitalizations and cardiovascular mortality compared to enelapril in chronic heart failure. furthermore, quality of life is improved. the decrease of nt-probnp levels during sacubitril-valsartan treatment is associated with reverse left ventricular remodeling and improved left ventricular systolic function. however, the underlying mechanisms that contribute to these symptomatic and prognostic benefits are largely unknown. the aim of this study is to evaluate left ventricular hemodynamics in patients treated with sacubitril-valsartan using non-invasive pressure-volume analysis.


Eligibility criteria:
inclusion criteria: * symptomatic heart failure (nyha functional class ii to iv) * reduced lv ejection fraction (≤ 40%) * clinical indication for therapy with sacubitril-valsartan exclusion criteria: * catecholamine therapy at inclusion * existing therapy with sacubitril-valsartan * planned cardiac resynchronization therapy (crt) within 6 months; inclusion at least 3 months after crt * planned mitral or aortic valve procedure within 6 months; inclusion at least 3 months after valve procedure * participation in another randomized heart failure trial * severe aortic or mitral valve lesion
role of acetazolamide and hydrochlorothiazide followed by furosemide in treating nephrotic edema

Conditions: Nephrotic Syndrome; Edema

Summary: the purpose of this study is to determine whether using furosemide following acetazolamide is effective in treating refractory edema associated with nephrotic syndrome.

edema is referred to increase in interstitial fluid that is clinically evident. the main causes of generalized edema are heart failure, renal failure, nephrotic syndrome, glomerulonephritis and chronic liver failure. in some cases, edema is treated by management of the underlying disease. however, in some other cases edema may persist and become more severe that needs adjuvant treatments. because use of diuretics such as furosemide and hydrochlorothiazide is not completely effective in treating severe refractory edema, use of some other diuretics is also recommended. in this double-blind clinical trial, weight and some lab data including blood urea nitrogen, serum creatinine, serum sodium, serum potassium, serum albumin, urine sodium, urine potassium, 24-hour urine volume, 24-hour urine protein and 24-hour urine creatinine of 20 random adult patients with nephrotic syndrome who have refractory edema and gfr\>60 ml/min/1.73m2 and are referred to nephrology clinic of shiraz university of medical sciences will be measured; the patients should not have hypokalemia and other causes of edema such as heart failure or cirrhosis. then the patients are divided into 2 groups with 10 members in each. the first group will be prescribed 40 mg of furosemide and 50 mg of hydrochlorothiazide and the second one will receive 250 mg of acetazolamide and 50 mg of hydrochlorothiazide daily for 1 week. then, weight and mentioned lab data will be measured again. after that, all the patients will have 40 mg of furosemide daily for 2 weeks. then, weight and mentioned lab data will be measured for one more time.

Eligibility criteria:
inclusion criteria: 1. having refractory edema due to nephrotic syndrome 2. having gfr\>60 ml/min/1.73m2 3. being able to come for weekly visit 4. having the minimum age of 18 years 5. signing the informed consent form exclusion criteria: 1. hypokalemia 2. pregnancy 3. renal transplant 4. active malignancy or infection 5. acidosis 6. using nsaids 7. having another causes of edema including liver cirrhosis, heart failure 8. neurologic or psychiatric problem hindering adherence to the study protocol

Keywords: edema nephrotic syndrome acetazolamide furosemide
pilot/pivotal study of dbs+rehab after stroke

Conditions: Stroke; Upper Extremity Paresis

Summary: the restore stroke study will evaluate the safety and effectiveness of dbs+rehab for treating arm weakness and reduced function after a stroke.

the restore stroke study combines two phases of study under one protocol (pilot/pivotal). the first phase has a sample size of 40 subjects. the second phase has an estimated sample size of 162 subjects which may be adjusted based on analysis of the first phase. each subject will be implanted with the dbs system, undergo dbs program optimization, and be randomized to test treatment (tt) or active-control treatment (ct). after randomization, all subjects will participate in a five-month outpatient rehabilitation therapy program. after five months of blinded randomized testing, subjects assigned to active-control treatment (ct) will cross over to receive test treatment (tt) and participate in a second five-month therapy program.

Eligibility criteria:
key inclusion criteria: * ischemic stroke, with an initial incident occurring between 12 months to 6 years before implant, resulting in residual upper extremity hemiparesis. key exclusion criteria: * previous or subsequent cerebrovascular events resulting in residual upper extremity impairment * brain lesions with significant involvement of the brainstem, cerebellum, or thalamus

Keywords: ischemic stroke deep brain stimulation dbs physical therapy rehabilitation brain stimulation
confirmatory study of prgn-2012 in patients with rrp

Conditions: Recurrent Respiratory Papillomatosis; Papillomavirus Infection; Papillomaviridae

Summary: the purpose of this confirmatory study is to provide further demonstration of the efficacy of prgn-2012 for the treatment of rrp in adults.

this is a single-arm, open-label confirmatory study of prgn-2012 in rrp patients with a history of repeated surgical debulking for the management of their disease. patients will be treated with prgn-2012 and followed for at least 12 months to evaluate for efficacy and safety endpoints.

Eligibility criteria:
key inclusion criteria: * age 18 years and older * clinical diagnosis of rrp requiring surgical intervention * performance status of ecog of 0-1 * sexually active participants (men and women) of reproductive potential must agree to use contraception. * all participants must have the ability to understand and willingness to sign a written informed consent key exclusion criteria: * severe acute or chronic medical or psychiatric conditions that, in the opinion of the investigators, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results and in the judgment of the investigator, would make the participant inappropriate for entry into this study. * participants receiving any prohibited medications including immunosuppressive medications and other treatments for rrp. * participants who had received any other investigational agents within the past 30 days. * pregnant women are excluded from this study

Keywords: human papilloma virus confirmatory study laryngotracheal disease papillomatous disease
rosiglitazone in treating patients with liposarcoma

Conditions: Sarcoma

Summary: rationale: rosiglitazone may help liposarcoma cells develop into normal fat cells. purpose: phase ii trial to study the effectiveness of rosiglitazone in treating patients who have liposarcoma.

objectives: * determine the clinical activity of rosiglitazone in patients with liposarcoma. * assess the impact of this regimen on markers of tumor proliferation and differentiation status in these patients using biologic and biochemical testing and correlative imaging. * determine the tolerance and safety of this regimen in these patients. outline: patients are stratified by histologic subtype (well differentiated vs dedifferentiated vs myxoid/round cell vs pleomorphic). patients receive oral rosiglitazone twice daily. treatment continues in the absence of disease progression or unacceptable toxicity. patients are followed at 1-3 weeks and then every 3 months thereafter. projected accrual: a total of 56-120 patients (14-30 per stratum) will be accrued for this study within 15 months.

Eligibility criteria:
disease characteristics: * histologically proven liposarcoma that is incurable with standard multimodality approaches (e.g., surgery and/or radiotherapy and/or chemotherapy) * well differentiated or * dedifferentiated or * myxoid/round cell or * pleomorphic * measurable disease * no clinically unstable brain metastases * no progression on prior troglitazone therapy for liposarcoma patient characteristics: age: * 18 and over performance status: * ecog 0-2 life expectancy: * at least 3 months hematopoietic: * absolute neutrophil count at least 1,000/mm3 * platelet count at least 90,000/mm3 hepatic: * bilirubin no greater than 2.0 mg/dl * sgot less than 5 times upper limit of normal renal: * creatinine no greater than 2.4 mg/dl cardiovascular: * no poorly controlled atrial arrhythmias, symptomatic angina pectoris, or myocardial infarction within the past 4 months * no symptomatic congestive heart failure, percutaneous transluminal coronary angioplasty, or coronary artery bypass graft within the past 3 months other: * not pregnant or nursing * negative pregnancy test * fertile patients must use effective barrier contraception * oral contraceptives are not considered effective contraception * no active retroviral disease * no condition that would preclude informed consent prior concurrent therapy: biologic therapy: * not specified chemotherapy: * see disease characteristics * prior chemotherapy allowed and recovered * no concurrent cytotoxic therapy endocrine therapy: * no concurrent hormonal therapy radiotherapy: * see disease characteristics * prior radiotherapy allowed and recovered * at least 6 months since prior radiotherapy to the sole site of measurable disease * concurrent localized radiotherapy to a single site of disease allowed if there are other sites of measurable disease surgery: * not specified

Keywords: adult liposarcoma recurrent adult soft tissue sarcoma